Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy
Open Access
- 7 February 2019
- journal article
- research article
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 17 (1) , 1-10
Abstract
Health system expenditure on cancer drugs is rising rapidly in many OECD countries given the costly new treatments and increased rates of use due to a growing and ageing population. These factors put considerable strain on the sustainability of health systems worldwide, sparking public debate among clinicians, pharmaceutical companies, policy-makers and citizens on issues of affordability and equity. We engaged Canadians through a series of deliberative public engagement events to determine their priorities for making cancer drug funding decisions fair and sustainable in Canada’s publicly financed health system. An approach to deliberation was developed based on the McMaster Health Forum’s citizen panels and the established Burgess and O'Doherty model of deliberative public engagement. Six deliberations were held across Canada in 2016. Transcripts were coded in NVivo and analysed to determine where participants’ views converged and diverged. Recommendations were grouped thematically. A total of 115 Canadians participated in the deliberative events and developed 86 recommendations. Recommendations included the review and regular re-review of approved drugs using ‘real-world’ evidence on effectiveness and cost-effectiveness; prioritisation of treatments that restore patients’ independence, mental health and general well-being; ensuring that decision processes, results and their rationales are transparent; and commitment to people with similar needs receiving the same care regardless of where in Canada they live. The next steps for policy-makers should be to develop mechanisms for (1) re-reviewing effectiveness and cost-effectiveness data for all cancer drugs; (2) making disinvestments in cancer drugs that satisfy requirements relating to grandfathering and compassionate access; (3) ensuring fair and equitable access to cancer drugs for all Canadians; and (4) fostering a pan-Canadian approach to cancer drug funding decisions.Keywords
Funding Information
- Canadian Partnership Against Cancer
This publication has 21 references indexed in Scilit:
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer controlSocial Science & Medicine, 2014
- From ‘trust us’ to participatory governance: Deliberative publics and science policyPublic Understanding of Science, 2014
- Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug ReviewCurrent Oncology, 2013
- Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008Acta Oncologica, 2012
- What Is Public Deliberation?Hastings Center Report, 2012
- Eliciting ethical and social values in health technology assessment: A participatory approachSocial Science & Medicine, 2011
- Overcoming barriers to priority setting using interdisciplinary methodsHealth Policy, 2009
- Public participation in health care priority setting: A scoping reviewHealth Policy, 2009
- Deliberating about BioethicsHastings Center Report, 1997